Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
Launches RSV Corp. to develop virosome vaccine technology
January 6, 2014
By: Kristin Brooks
Managing Editor, Contract Pharma
Astellas Pharma and ClearPath Development Co. have entered a strategic partnership to form a portfolio of development companies focused on vaccines for infectious diseases. The partnership will support Astellas’ global vaccine franchise with the launch of the first company, RSV Corp. (RSVC). Astellas will fund RSVC’s development of a virosome vaccine technology, licensed from Mymetics Corp., for respiratory syncytial virus (RSV), through Phase IIb proof-of-concept. Astellas will have exclusive rights to acquire RSVC, as well as further develop and commercialize the vaccine. “This partnership highlights our commitment to build a global vaccine business and represents a highly efficient model for bringing innovative vaccines to market. It is also a unique opportunity for Astellas to utilize external cutting-edge science and technology to enhance our ability to generate innovative drugs, as part of our ‘Reshaping Research Framework’ program announced in May, 2013,” said Kenji Yasukawa, senior vice president and chief strategy officer, Astellas. “Together we are harnessing our collective resources to accelerate development of this promising, early stage asset and will replicate this scalable, outcome driven model across future portfolio companies,” said Chuck Finn, Ph.D., chairman, ClearPath Development Co. Mymetics will collaborate with RSVC on the development of the vaccine on preclinical activities including nonclinical evaluation, formulation development, and manufacture. Mymetics is eligible to receive upfront and proof-of-concept milestone payments of as much as $82 million, as well as royalties and other payments. “The financial backing and commercial experience of Astellas combined with ClearPath’s development expertise and our continued program involvement are unique factors which all work to increase the likelihood of success,” said Ronald Kempers, chief executive officer, Mymetics. “We anticipate RSV will be the first of many vaccine constructs that can be generated from our proprietary second-generation virosome platform.”
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !